Episode 21. Newly Diagnosed Mantle Cell Lymphoma
Blood Cancer Talks
00:00
The Triangle Trial: A Complicated Study Design
The triangle trial, which you presented the first results at American Society Humanology meeting in December 2022. What I think are indeed practice changing results. PFS was improved by 15% after three years, so really a major benefit and even overall survival was improved by 5%. So that's one point. The other comparison was, and that's even more complicated, the head-to-head comparison. And there, we did not dare to believe that eyebrow-bruitinib is better than autologous transplant,. We said, well, it should not be worse.
Transcript
Play full episode
